Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery. It also provides ActivaScrew Cannulated that offers a range of fully threaded and partially threaded cannulated screws for fixation of fractures and osteotomies; ActivaScrew Interference, a tool for multiple uses regarding bone fractures, osteotomies, arthrodesesm, and bone grafts; ActivaScrew Interference TCP, a biocomposite interference screw; and RemeOs Screw, a magnesium screw implants. The company was formerly known as BCI Bioabsorbable Concepts Oy. The company was incorporated in 1998 and is headquartered in Tampere, Finland.
Frequently asked questions
What sector does Bioretec Oy (BRETEC) operate in?
Bioretec Oy belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Bioretec Oy (BRETEC) current stock price?
As of the latest data, Bioretec Oy stock price is €0.02, with a previous close of €0.03. Bioretec Oy lost -€0.00 in the last trading session, representing a -17.14% loss.
What is Bioretec Oy (BRETEC) current market capitalization?
Bioretec Oy market cap is approximately 31.13 million.
What is Bioretec Oy (BRETEC) Earnings Per Share (EPS)?
The trailing EPS is -€0.03.
Does Bioretec Oy (BRETEC) pay dividends?
No. Bioretec Oy does not pay a dividend.
When is Bioretec Oy (BRETEC) next earnings report?
Bioretec Oy is expected to release its next earnings report on September 30, 2025.
What is Bioretec Oy (BRETEC) beta (volatility) score?
Bioretec Oy has a beta of 1.141, meaning its volatility is roughly in line with the market.
